glp-1 agonist alcohol Therapeutics and Their Emerging Role in and Substance Use Disorders: An Endocrinology Primer GLP-1 Alcohol Cravings: How Ozempic

Food and Drug Administration approved the first GLP-1 drug for type 2 diabetes in 2005 and another, the first for weight loss, in 2014

GLP-1R agonists effects on cardiovascular events The first pieces of evidence of the potential clinical benefit of GLP-1 agonists have emerged recently, pointing to a decrease of major adverse cardiovascular and cerebrovascular events (MACCE) including stroke, MI, cardiac mortality, acute coronary syndrome, and revascularization procedures

Brain-derived neurotrophic factor (BDNF) is important for neurogenesis, and various depressive symptoms arise from decreased BDNF levels (Sahay and Hen, 2007)

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

Supplement ingredients lack this precision mechanism

Individual Metabolic Needs The choice between GLP-1 and GIP medications can depend on an individuals metabolic profile